What does this research mean for the field?

Question

Accepted Answer

Prostate specific antigen (PSA)-based screening substantially decreases prostate cancer mortality, though non-attendance, initiating screening after age 60, and terminating screening at age 70 are associated with increased mortality risk. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial

Discussion

Member takes

Overview

Key Points

Cite This Study